This website uses its own and third party technical cookies, solely to ensure enhanced navigation and to gather anonymous statistical navigation data without any user profiling.

If you wish to learn more or deny consent to all or some cookies click here.

If you access any element below this banner you automatically consent to the use of cookies.

Accept

Staff Dirigenziale

Massimo Di Martino

President of Galileo Research Executive Board

Massimo Di Martino has served as Managing Director of Ethical Drugs in istituto Gentili S.p.A. (Pisa, Italy). Since 1997 he is President and managing Director of Abiogen Pharma S.p.A. He has been Member of the Board in several companies like Società Aurelia, representing Pisa Municipality, Società Interporto Toscano “A. Vespucci”, appointed by Pisa and Livorno Municipality and Cassa di Risparmio di Pisa S.P.A. Massimo Di Martino holds degrees in Economics (Università degli Studi di Pisa). He has been member of Farmindustria Giunta for long time and currently he is Vice President of Biotech Group of Farmindustria. Recently, he has been invited to join the deontology control Committee of Farmindustria.

 

Paolo Baroldi

Galileo Research Executive Board Member

Paolo Baroldi, MD, PhD, has served as Senior Vice President of Clinical Development and Chief Medical Officer since 2009. Previously, Dr. Baroldi was Senior Vice President of Clinical Development and Chief Medical Officer at Supernus Pharmaceutical (Rockville, MD), Vice President of Corporate Drug Development and Chairman of the R&D Board at Chiesi Farmaceutici SpA, and the Global Head of Clinical Pharmacology at Novartis AG. Dr. Baroldi holds degrees in medicine and surgery and a PhD in clinical pharmacology from the University of Milan, and an Executive MBA from Harvard University. Currently, he is Senior Vice President and Chief Medical Officer at Vanda Pharmaceuticals.

 

Alberto Bresci

Chief Executive Officer and Galileo Research Executive Board Member

Alberto Bresci has a long-time career experience in Marketing, Business Development and Strategic Planning in the pharmaceutical sector, including significant experience in R&D economics. In 2007 he joined MDM Holding S.P.A. (owner of Abioge Pharma S.p.A. and Galileo Research S.r.L.).

 

Silvia Trasciatti

Chief Scientific Officer

Silvia Trasciatti has served as Head of Preclinical Research in istituto Gentili S.p.A. (Pisa, Italy) and as Director of Research Center of Abiogen Pharma S.p.A. Since 2008 she has been R&D Division Director of Abiogen Pharma S.p.A. She is Member of the Scientific Advisory Board of Mediapharma S.r.L.. Silvia Trasciatti holds a graduate degree in Biological Sciences (University of Pisa), a post-graduate 3-year specialization degree in Biotechnology (University of Milano) and a Master in Nutritional Science (University of Firenze). She is member of the Advanced Therapies Working Group of the Scientific Committee in Farmindustria and of the Advanced Therapies Working Group in Assobiotec. Currently, she is Chief Scientific Officer in Galileo Research.

 

Fabrizio Nannipieri

Chief Medical Officer

Fabrizio Nannipieri, MD, has served as medical adviser of Medical Department in Ciba-Geigy. Then he was Clinical Research Coordinator in Istituto Gentili S.p.A. and subsequently Clinical Research Director in Abiogen Pharma S.p.A. Fabrizio Nannipieri has also been Scientific Director both in Istituto Gentili S.p.A. or Abiogen Pharma S.p.A. Dr. Nannipieri holds degrees in medicine and surgery and a specialization in Immunohematology from the University of Pisa. Currently he is Medical Affairs Director in Abiogen Pharma S.p.A. and Chief Medical Officer in Galileo Research.